



ColoPlex  **PLUS**™
Fight Cancer. Detect Early.

COMING
SOON!

A SIMPLE BLOOD TEST

TO DETECT EARLY RISK OF COLORECTAL CANCER

PATIENTS ARE MORE LIKELY TO PARTICIPATE IN CRC SCREENING PROGRAMS WHEN A BLOOD TEST IS BEING OFFERED COMPARED TO A FECAL TEST¹

Preliminary data for 241 prospectively enrolled clinical subjects indicated that early detection of CRC and Adenoma is achievable with a simple blood test².

SIMPLE BLOOD TEST

Convenient for patients:

- No messy fecal preparation or stool handling.
- Can be part of annual health check-up to improve compliance.
- Potential alternative screening method for those declining colonoscopy and stool testing methods¹.

EARLY CANCER DETECTION

ColoPlex PLUS preliminary data show 90% specificity and 84.3% sensitivity².

- CRC third most diagnosed cancer³.
- 2nd leading cause of cancer death³.
- CRC detected at Stage 1 has a 90%+ survival rate³.
- A blood test will drive compliance with current screening recommendations¹.

All elevated ColoPlex PLUS results should be confirmed by colonoscopy. ColoPlex PLUS will not replace colonoscopy but can be used as an aid in the diagnosis of colorectal cancer.

COLOPLEX PLUS IS A MULTI-OMIC PANEL THAT COMBINES PROTEIN AND MOLECULAR BIOMARKERS ENHANCED BY AI SOFTWARE.

DNA methylation of the SEPT9 and other tumor-associated genes is increased in colorectal cancer. The molecular biomarker, mSEPTIN 9 can be measured in blood plasma using real-time PCR technology. The protein biomarkers are measured as a multiplex immunoassay using labeled microsphere bead technology.

Table 1. Comparison of ColoPlex PLUS versus FIT sensitivity for colorectal cancer at stages 1 and 2 and stages 1, 2, and 3².

	ColoPlex PLUS	FIT
Stage 1 & 2	77.1%	70.0%
Stage 1, 2, & 3	84.1%	73.3%

1: Liles, E. G., Coronado, G. D., Perrin, N., Harte, A. H., Nungesser, R., Quigley, N., Potter, N. T., Weiss, G., Koenig, T., & deVos, T. (2017). Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. *Cancer Treatment and Research Communications*, 10, 27-31. <https://doi.org/10.1016/j.ctarc.2016.12.004>

2: New Day Diagnostics, LLC. (2022) Unpublished internal company data.

3. Colorectal Cancer Survival Rates | Colorectal Cancer Prognosis. (n.d.). [www.cancer.org](https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html). <https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html>

New Day Diagnostics. All rights reserved. The trademarks mentioned herein are the property of New Day Diagnostics or their respective owners. NOT FOR SALE IN USA.